文献速递乳腺癌

2008至2017年荷兰新发HER2阳性转移性乳腺癌接受全身治疗患者的总生存:一项基于人群的队列研究

Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients.
PubMed 文献 · Eur J Cancer · 2025-04-26

该研究基于荷兰癌症登记数据,纳入2008至2017年确诊的新发HER2阳性转移性乳腺癌患者1458例,分析每两年期间的总生存及治疗使用变化。结果显示,与2008-2009年相比,2016-2017年确诊患者的中位OS从30.9个月提高至57.3个月,调整后风险比为0.49,HER2靶向治疗及帕妥珠单抗使用增加。

要点

  • 2008-2009年确诊患者中位OS为30.9个月,2016-2017年为57.3个月,趋势P<0.001。
  • 调整后风险比为0.49(95%CI 0.40-0.59),提示死亡风险降低。
  • 任何HER2靶向治疗使用从64%增至84%,帕妥珠单抗方案从0%增至67%。

核心结论

  • 2008至2017年荷兰新发HER2阳性转移性乳腺癌患者的总生存十年间翻倍。
  • 转移表现随时间无变化,总生存改善最可能归因于治疗进步。

研究设计与样本

  • 基于荷兰癌症登记(Netherlands Cancer Registry)的基于人群的队列研究。
  • 纳入2008-2017年确诊的新发HER2阳性转移性乳腺癌患者1458例。
  • 按每两年期间使用Kaplan-Meier法估计总生存,采用趋势log-rank检验和多变量Cox比例风险分析,调整基线特征和局部治疗。

主要发现

  • 纳入1458例患者,99%(1452/1458)为女性,53%(775/1458)诊断时年龄50-74岁。
  • 2008-2009年确诊患者中位OS为30.9个月(95%CI 25.0-35.4),2016-2017年为57.3个月(95%CI 46.7-68.1),趋势P<0.001。
  • 调整后风险比=0.49(95%CI 0.40-0.59)。
  • 任何HER2靶向治疗使用从64%(178/279)增至84%(287/340),帕妥珠单抗为基础的治疗从0%增至67%(227/340)。
  • 手术使用保持稳定,原发肿瘤放疗从16%(44/279)增至22%(76/340),转移灶放疗从15%(42/279)增至26%(88/340)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study aims to determine whether real-world overall survival (OS) of patients with de Novo HER2-positive (HER2 +) metastatic breast cancer (MBC) in the Netherlands improved over time. METHODS: Data of patients diagnosed with de Novo HER2 + MBC in 2008-2017 were retrieved from the Netherlands Cancer Registry. OS was estimated per two-year period using the Kaplan-Meier method and compared using the log-rank test for trend and the multivariable Cox proportional hazards analysis, adjusted for baseline characteristics and local therapy. First-given systemic and local therapy use was determined per two-year period. RESULTS: Among 1458 patients included, 99 % (1452/1458) were female and 53 % (775/1458) aged 50-74 years at diagnosis. Comparing patients diagnosed with de Novo HER2 + MBC in 2008-2009 versus 2016-2017, the median OS improved from 30·9 months (95 %CI:25·0-35·4) to 57·3 months (95 %CI:46·7-68·1) (p-value for trend<0·001) (adjusted hazard rate ratio =0·49, 95 %CI:0·40-0·59). The use of any HER2-targeted therapy increased from 64 % (178/279) to 84 % (287/340), while the use of pertuzumab-based therapy increased from 0 % to 67 % (227/340) over the same period. The use of surgery remained stable over time, while radiotherapy use for both the primary tumour and metastases increased in recent years, from 16 % (44/279) and 15 % (42/279) in 2008-2009-22 % (76/340) and 26 % (88/340) in 2016-2017, respectively. CONCLUSION: OS has doubled over ten years, for patients diagnosed with de Novo HER2 + MBC in the Netherlands between 2008 and 2017. No change in metastatic presentation was observed over time, suggesting the improved OS is most likely explained by treatment improvements.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ding N, Hermans KEPE, van Nijnatten TJA, et al. Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients. Eur J Cancer. 2025. PMID: 40306118. doi:10.1016/j.ejca.2025.115475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。